Brussels - Delayed Quote EUR

Hyloris Pharmaceuticals SA (HYL.BR)

6.08

0.00

(0.00%)

At close: January 10 at 4:53:27 PM GMT+1

Hyloris Reports Full Year Results for 2023 & Provides Business Outlook

Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Total revenue and other income amounted to €4.4 millionStronger growth expected in 2024 of both sales and gross margin, mainly fueled by the recent launch in the U.S. of Maxigesic® IV and Podofilox gel, the global roll out of Maxigesic IV® and commercial dealsIncreased operating R&D expenses while net operating cash outflow remained stable versus 2022Significant R&D progress including clinical and regulatory achievements with

GlobeNewswire 9 months ago

HYL.BR
0.00%
Communication at the request of the FSMA on the transactions with Qliniq

Communication at the request of the FSMA on the transactions with Qliniq Revision of 2022 and half-year of 2023 (HY 2023) financial statements following a correction of a non-cash error in the accounting treatment of the transactions with Qliniq announced on 20 January 2023HY-088 and HY-038 considered as a non-monetary exchange under IAS 38.45 in 2023No impact on the cash flow and cash position Liège, Belgium – 14 March 2023 – 07:00AM CET – Regulated Information – Inside informaition - Hyloris P

GlobeNewswire 9 months ago

HYL.BR
0.00%
Hyloris to Report 2023 Full-Year Results on 14 March 2024

Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET. Following the release, the company will host a live webcast to discuss 2023 results and the outlook for 2024. Participants will have a ch

GlobeNewswire 9 months ago

HYL.BR
0.00%
Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Maxigesic® IV, a Potent Non-opioid Painkiller, Marketed in the U.S. under the Tradename Combogesic® IVMaxigesic® IV approved in Canada Liège, Belgium – 27 February 2024, 06:00 PM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Hikma Pharmaceutical

GlobeNewswire 10 months ago

HYL.BR
0.00%
Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

Innovative oral care solution aims to benefit patients taking blood thinning medications, who have an increased risk of prolonged bleeding during and after dental procedures Approximately 280 patients in the EU and U.S. will be randomized to receive either tranexamic acid oral solution or placeboLast patient out expected around end of 2024Study results expected first half of 2025 Liège, Belgium – February, 14 2024 – 6PM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Bruss

GlobeNewswire 10 months ago

HYL.BR
0.00%
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 291 Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information – Hyloris Pha

GlobeNewswire 11 months ago

HYL.BR
0.00%
Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)

Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) Equal Partnership with AFT Pharmaceuticals for Development of a Drug Releasing Mucoadhesive Film for VLS (HY-091)Limited Availability of Approved Treatment Options in VLS Liège, Belgium – 18 January 2024, 07:00 PM CET – Regulated information – Inside information -Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing ex

GlobeNewswire 11 months ago

HYL.BR
0.00%
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)

Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity developed in collaboration with Pleco Therapeutics Liège, Belgium – 16 January 2024, 07:30PM CET – Non-Regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces tha

GlobeNewswire 11 months ago

HYL.BR
0.00%
Pleco Therapeutics receives FDA Orphan Drug Designation

Ivo Timmermans, MD MBA, Chief Executive Officer Ivo Timmermans, Chief Executive Officer, Pleco Therapeutics BV NIJMEGEN, The Netherlands, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics BV’s lead compound, PTX-252 for the treatment of Acute Myeloid Leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. The FDA’s designation acknowledges the

GlobeNewswire 11 months ago

HYL.BR
0.00%

Performance Overview

Return	HYL.BR	BEL 20
YTD	-13.14%	+0.19%
1-Year	-52.50%	+13.76%
3-Year	-67.14%	-1.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hyloris Pharmaceuticals SA (HYL.BR)

Hyloris Reports Full Year Results for 2023 & Provides Business Outlook

Communication at the request of the FSMA on the transactions with Qliniq

Hyloris to Report 2023 Full-Year Results on 14 March 2024

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada

Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)

Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)

Pleco Therapeutics receives FDA Orphan Drug Designation

Performance Overview